Using decision support platforms to enhance cancer diagnostics: the importance of vigilance and wise decision-making

The advent of next-generation sequencing (NGS) represents the onset of a new era in personalised therapy. The treatment landscape for cancer is shifting from the conventional ‘one-size-fits-all’ approach of chemotherapy and radiotherapy to a more personalised strategy, in which therapeutic drugs are selected based on the comprehensive genomic profile of cancer. Although NGS has revolutionised personalised treatment, it has also introduced the complex challenge of managing a deluge of genetic variants, requiring standardised interpretation and consistent clinical application of these variants.1